cancer genomics

Cohesin mutations cause dysregulations in alternative splicing, contributing to tumor initiation and progression, a study finds. 

DNA sequencing can identify mutations that predict recurrence of renal cell carcinoma and may help low-risk patients avoid unnecessary treatment, a study finds.

Two studies find that tumor-specific antigens are often peptides that result from a splicing event between exons and transposable elements.

This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.

Most differences in gene expression among cells within a tumor are likely due to environment or noise, a study suggests. 

Disturbing circadian rhythms in organoids and mice increases intestinal tumor growth, findings that may explain a recent rise in colon cancer among young adults, the researchers behind the work say.

A previously overlooked enzyme called APOBEC3A is linked to the most prevalent mutational signatures in cancer cell lines, a study finds.

Tumors contain thousands of genetic changes, but only a few are actually cancer-causing. A quicker way to identify these driver mutations could lead to more targeted cancer treatments.

Analyzing the whole genome sequences of more than 18,000 tumors, researchers catalog nearly 60 new patterns of mutations that could inform cancer treatment.

This year revealed just how much scientists have learned about the disease, from how animals become naturally cancer-resistant to how tumor cells harness extracellular DNA to develop rapid drug resistance.

The Scientist spoke with University of Liverpool aging and longevity researcher João Pedro de Magalhães about how human biases can influence scientific priorities and outcomes in genetics.

In the last decade, researchers have come to realize that tumors harbor bits of extrachromosomal DNA that can drive malignancy.

An interrogation of the whole genomes of more than 2,600 cancers yields clues about the genetic drivers of malignancy, how tumors evolve, and more.

Its screen for selected variants of some disease-linked genes gives customers an incomplete picture of their risk—do they know?

Fly avatars bearing multiple genetic changes akin to those of a cancer patient lead to a tailor-made treatment that has shrunk the patient’s tumors.